Business Wire

EXSCIENTIA

2.1.2024 13:01:39 CET | Business Wire | Press release

Share
Professor Andrew L. Hopkins appointed Commander of the Order of the British Empire (CBE)

Professor Andrew Hopkins FRS FMedSci, founder and Chief Executive of Exscientia plc (Nasdaq: EXAI), has been appointed Commander of the Order of the British Empire (CBE) for services to Science and Innovation by His Majesty King Charles III. The distinguished honour comes as part of HM The King’s 2024 New Year Honours List, recognising the achievements and service of extraordinary people across the UK who have been recommended by the Prime Minister based on an independent assessment process.

The appointment reflects Andrew’s life-long passion for harnessing the power of innovative technologies to discover and develop high-quality medicines to benefit patients. This recognition follows multiple previous awards and prestigious honours recently received by both Andrew and Exscientia, the AI-driven precision medicine company he leads.

After publishing pioneering scientific papers on how machine learning and generative algorithms could be used to design novel drug leads, Andrew founded Exscientia in 2012 to create and develop the best possible drugs in the fastest and most effective manner. As the company’s CEO, Andrew led the group who discovered the first AI-designed drugs to enter human clinical trials. Today, he heads a global team of around 450 scientists and technology experts based in Oxford, UK, and globally. Prior to Exscientia, Andrew held the Chairs of Medicinal Informatics and Translational Biology at the University of Dundee and spent a decade at Pfizer Inc. leading various informatics groups. He received his doctorate in biophysics from the University of Oxford and his LLD from the University of Dundee where he also holds an Honorary Chair.

For its end-to-end AI-driven precision medicine platform, Exscientia won the Prix Galien USA for Best Digital Health Solution in late 2022, as well as the Prix Galien UK in the same category in May 2023. Also in May this year, Andrew was elected for life to two of the UK’s national academies in recognition of “exceptional contributions to science”, as Fellow of the Royal Society, the world’s oldest independent academic scientific body, and as Fellow of the Academy of Medical Sciences. In September, Andrew was featured on the inaugural TIME 100 AI list of most influential people in AI, while most recently, in November 2023, Exscientia was named to the inaugural Fortune 50 AI Innovators list.

“I’m truly humbled by this extraordinary recognition of the work of my outstanding team that I am privileged to lead,” said Andrew. “Our goal at Exscientia of utilising advanced technology to accelerate the design of new drugs, an idea that originated during my doctorate, has gained substantial momentum in changing the way future therapies may be created, evaluated and brought to patients in need of fast, effective and affordable treatment. Based on our progress so far, we believe all drugs will be designed and developed with AI and that this approach holds the key to transforming the trajectory of human health forever.”

About Exscientia

Exscientia is an AI-driven precision medicine company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our internal pipeline is focused on leveraging our precision medicine platform in oncology, while our partnered pipeline broadens our approach to other therapeutic areas. By pioneering a new approach to medicine creation, we believe the best ideas of science can rapidly become the best medicines for patients. Visit us at https://www.exscientia.ai or follow us on Twitter @exscientiaAI.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240102661842/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

PANECO to Exhibit at EuroShop 2026 -- Seeking Global Sales Partners for Sustainable Materials Made from Textile Waste --9.2.2026 08:00:00 CET | Press release

Japanese-Made Textile Recycling Boards Supporting Sustainability in Retail PANECO®, a textile circularity and sustainable materials platform developed by WORKSTUDIO Co., Ltd. (Tokyo, Japan), will exhibit at EuroShop 2026, held in Düsseldorf, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260203145499/en/ Textile Recycling Board | PANECO Visitors to EuroShop are actively searching for sustainable materials that can be implemented in commercial spaces and furniture. Across Europe and globally, demand for the practical implementation of sustainable materials is rapidly increasing. In this environment, materials are expected to be not only environmentally responsible, but also scalable, reliable, and commercially viable. In response to this market demand, PANECO® transforms textile waste into high-quality recycled boards, offering sustainable solutions for commercial spaces and furniture. These materials are designed fo

Tigo Energy EI Residential Solar-plus-Storage Solution Certified with Romanian Grid Operators9.2.2026 06:00:00 CET | Press release

With approval from Distribuție Energie Electrică România (DEER), Distribuție Oltenia, and Rețele Electrice, Tigo expands offering in one of Europe’s fastest-growing residential solar markets. Tigo Energy, Inc. (NASDAQ: “TYGO”) (“Tigo” or “Company”), a leading provider of intelligent solar and energy software solutions, today announced the successful certification of the Tigo EI Residential solar-plus-storage solution with Romanian distribution system operators, further expanding market reach of Tigo products across Europe. Following the successful completion of their respective grid-compliance and certification procedures with Distribuție Energie Electrică Romania (DEER), Distribuție Oltenia, and Rețele Electrice, single-phase and three-phase configurations of the EI Residential solution are now fully listed and approved for use in the Romanian market. With 2026 expected to be another strong year for solar growth nationally, the Tigo EI Residential system becomes an important addition

Levi’s® Brand Debuts “Behind Every Original” Campaign With Super Bowl Film Highlighting Backstories and Backsides9.2.2026 01:38:00 CET | Press release

The Levi’s® brand today launched “Behind Every Original,” a bold new global campaign that celebrates the people who push culture forward — with one cheeky twist. Debuting during the Super Bowl with the anthem film “Backstory,” directed by Kim Gehrig, the Levi’s® brand flips expectations by showcasing both celebrity icons and everyday Originals exclusively from the backside, letting them share their game-changing Levi’s® backstory. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260208761156/en/ Doechii Why the backside? Because it's the most iconic point of view of Levi’s® jeans. The arcuate stitching, silhouette and the Red Tab™ instantly signal originality. For over 150 years, Levi’s® jeans have been the uniform of cultural catalysts who step off the beaten path and shape what comes next in music, sport, fashion and art. They have been the uniform of the movements and moments that have changed the world and shaped culture —

DCO Concludes 5th General Assembly with Adoption of the Kuwait Declaration on Responsible AI for Global Digital Prosperity7.2.2026 16:41:00 CET | Press release

The Digital Cooperation Organization (DCO) has concluded its fifth General Assembly, with Member States adopting the Kuwait Declaration on Responsible AI for Global Digital Prosperity and agreeing on actions to advance inclusive, trusted, and scalable digital transformation in the AI age. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260207972901/en/ DCO concludes 5th General Assembly with adoption of the Kuwait Declaration on Responsible AI for Global Digital Prosperity (Photo: AETOSWire) Convened on 4–5 February 2026 under the Presidency of the State of Kuwait, the General Assembly brought together Ministers and Representatives of Member States, alongside Observers, partners, and guest countries, to review progress against the DCO 4-Year Agenda (2025–2028), take joint decisions on multilateral initiatives, and translate shared ambition on AI into delivery. Ministers and representatives reaffirmed their commitment to inclu

Rapid Medical™’s DISTALS Trial Overwhelmingly Positive, Demonstrating Superior Reperfusion with TIGERTRIEVER™ 13 in Medium Vessel Stroke6.2.2026 20:30:00 CET | Press release

TIGERTRIEVER™ 13 is the first device shown to meet safety and effectiveness endpoints for restoring blood flow in smaller but critical areas of the brain, accounting for almost 50% of all ischemic strokes Rapid Medical™, a leading developer of active endovascular devices, today announced late-breaking results from the DISTALS multicenter, randomized controlled trial showing that TIGERTRIEVER™ 13 achieved superior brain tissue reperfusion with an excellent safety profile when compared with medical management in medium vessel occlusion (MVO) stroke. The findings were presented in the main closing session at the 2026 International Stroke Conference (ISC). Top-line results showed that the TIGERTRIEVER™ 13 arm demonstrated 3x more successful reperfusion without symptomatic intracranial hemorrhage (sICH) compared to medical management–86.3% vs 27.7% (p < 0.001). Notably, zero sICH events were reported in the randomized treatment arm treated with TIGERTRIEVER 13. By comparison, sICH rates rep

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye